BioNTech, Pays

BioNTech Pays $205 Million for FDA Speed Lane While Roche Picks Up the Research Tab

Published on 11/20/2026 at 12:02 | Editorial boerse-global.de
BioNTech pays Scholar Rock $205M for an FDA priority review voucher and shifts research costs to Roche and Genentech from 2027.
BioNTech Pays $205 Million for FDA Speed Lane While Roche Picks Up the Research Tab Illustration mit AI erstellt.

BioNTech has agreed to buy a priority review voucher from Scholar Rock Holding Corporation for US$205 million in cash, a deal struck last week that the German biotech intends to deploy on a future marketing application for one of its advanced oncology pipeline candidates. The transaction, which remains subject to customary conditions including US antitrust clearance, buys the company a faster track through the Food and Drug Administration's review process.

The voucher purchase sits alongside a separate move to lighten BioNTech's research burden. The company has exercised an option in its collaboration with Roche and Genentech under which the two partners will, from January 1, 2027, generally shoulder future research and development costs for the program in question. The ongoing adjuvant pancreatic cancer study is to continue as planned.

Analyst Adjusts Target as Shares Slide

JPMorgan left its rating on BioNTech at "Neutral" yesterday while nudging its price target to $93 from $92, with analyst Jessica Fye behind the revision. The stock has been under pressure across two sessions. It shed 2.1% yesterday to close at €74.20, and the decline carried into today with a 1.5% drop to €73.05. The wider US equity market also retreated, with the Associated Press attributing the softness to concerns surrounding AI stocks.

Should investors sell immediately? Or is it worth buying BioNTech?

On the operating side, BioNTech reported third-quarter 2026 revenue of €1.29 billion and raised the midpoint of its full-year 2026 revenue guidance. Forecasts for adjusted research and development costs and for adjusted sales and administrative expenses were left unchanged.

Clinical and Legal Fronts Both Active

In oncology, BioNTech advanced a Phase 3 trial in triple-negative breast cancer on October 22 together with Gilead Sciences, testing pumitamig in combination with Gilead's sacituzumab govitecan.

The legal picture is widening in parallel. Arbutus Biopharma and Genevant expanded their patent litigation against Pfizer and BioNTech last Friday by filing additional suits in Japan. They also brought a newly granted lipid nanoparticle patent into the existing Canadian proceedings. The claims target technology used in the Pfizer and BioNTech COVID-19 vaccines.

Ad

BioNTech Stock: New Analysis - 20 November

Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated BioNTech analysis...

Disclaimer...
en | US09075V1026 | BIONTECH | boerse | 70539685 |